Contact
searchSearch
HMP Global

HEOR Topic Center

Featured Article

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
Headshot of Merle Diamond, MD, Diamond Headache Clinic, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Migraine's Impact on Productivity, Quality of Life
05/19/2022
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH, director, Diamond Headache Clinic and inpatient headache unit at Saint Joseph Hospital, offers insight into the prevalence and burden of migraine, as well as risk factors that can cause migraine to progress from...
Merle Diamond, MD, AQH,...
05/19/2022
First Report Managed Care
Headshot of Gary Owens, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
How Payers Can Use Clinical, Value Comparison Data for Atopic Dermatitis Therapy
09/24/2021
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of Gary Owens Associates, shares his thoughts on the challenges of choosing treatment options for patients with atopic dermatitis, and highlights key takeaways for payers from a recent ICER report which compared the...
Gary Owens, MD, president of...
09/24/2021
First Report Managed Care
News
Screening for Spinal Muscular Atrophy Enhances Nusinersen Cost-Effectiveness
01/22/2021
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for...
01/22/2021
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
Discussing Treatment Paradigm Shifts, Successful Therapy Options for Atopic Dermatitis
Videos
Discussing Treatment Paradigm Shifts, Successful Therapy Options for Atopic Dermatitis
11/13/2020
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate professor of dermatology, University of Arkansas for Medical Sciences, describes challenges involved with treating atopic dermatitis, highlights the benefits of dupilumab—particularly among pediatric patients,...
Vivian Shi, MD, FAAD, associate...
11/13/2020
First Report Managed Care
Literature Review
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
10/23/2020
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen...
10/23/2020
First Report Managed Care
Weighing Benefits and Challenges to Effectively Treat Atopic Dermatitis
Podcasts
Weighing Benefits and Challenges to Effectively Treat Atopic Dermatitis
09/16/2020
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake Forest University School of Medicine, discusses the real-world effectiveness of dupilumab for the treatment of atopic dermatitis, how this data is relevant for payers, and stresses the importance of studying...
Steven Feldman, MD, PhD, Wake...
09/16/2020
First Report Managed Care
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
News
Examining the Cost-Effectiveness of DLBCL Treatment
08/27/2020
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed...
08/27/2020
First Report Managed Care
Discussing Effectiveness, Persistence Rates for Atopic Dermatitis Therapy
Podcasts
Discussing Effectiveness, Persistence Rates for Atopic Dermatitis Therapy
08/13/2020
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology at The George Washington University School of Medicine and Health Sciences, Washington, DC, offers insight into his real-world data study in which he and his colleagues...
Jonathan Silverberg, MD, PhD,...
08/13/2020
First Report Managed Care

Newsfeed

News
Added SGLT2 Inhibitor Therapy of Intermediate/Low Value in Heart Failure With Preserved Ejection Fraction 
03/29/2023
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the lifetime cost effectiveness of standard therapy with vs without an SGLT2 inhibitor to reduce the risk of adverse outcomes in patients with heart failure.
Researchers investigated the...
03/29/2023
First Report Managed Care
News
Screening for Spinal Muscular Atrophy Enhances Nusinersen Cost-Effectiveness
01/22/2021
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for spinal muscular atrophy provides improved economic value for payers and patients when nusinersen is available,” wrote researchers from Weill Cornell Medical College and the University of Utah School of...
“Universal newborn screening for...
01/22/2021
First Report Managed Care
News
Cost-Effectiveness of Implantable Loop Recorder Monitoring After Stroke in Line Wth Other Therapies
12/06/2020
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year gained in the range of other publicly funded therapies
For detecting occult atrial...
12/06/2020
First Report Managed Care
News
Examining the Cost-Effectiveness of DLBCL Treatment
08/27/2020
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed or refractory diffuse large B-cell lymphoma have limited treatment options and poor prognoses, researchers recently examined the cost-effectiveness of treatments for this patient population.
Because patients with relapsed...
08/27/2020
First Report Managed Care
Conference Insider
Latanoprostene Bunod Proves Cost-Effective for Primary Open-Angle Glaucoma
11/20/2019
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019. 
When compared to prostaglandin...
11/20/2019
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Literature Review

Literature Review
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
10/23/2020
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen...
10/23/2020
First Report Managed Care
Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

Literature Review

Literature Review
Regulating the Use of CAR-T Therapy Outside of the Drug Paradigm
10/23/2020
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen receptor T-cell (CAR-T) therapies are regulated as drugs—often leading to higher prices and barriers to access for patients, as well as financial strains for hospitals. However, in a recent insights article in JAMA...
Currently, chimeric antigen...
10/23/2020
First Report Managed Care
Literature Review
Improved Therapy Options for Patients with Neuroendocrine Tumors
02/23/2019
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are thought to arise from cells throughout the diffuse endocrine system. According to a report published in JAMA Oncology, the incidence and prevalence of NETS are steadily rising, though for reasons not well...
Neuroendocrine tumors (NETs) are...
02/23/2019
First Report Managed Care
Literature Review
Promising Outcomes for SER-109: A New Approach to Managing Recurrent CDI
10/23/2023
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109 effectively treat CDI, but results show that it can even reduce recurrence. A major benefit when it comes to associated health care costs for patients.
Not only does SER-109...
10/23/2023
First Report Managed Care
Literature Review
Comparing IL-6 Inhibitors and Glucocorticoids in Treating PMR: SAPHYR Trial Results
10/16/2023
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided researchers with valuable insights into alternative treatment options for PMR due to its larger patient population. The effectiveness of sarilumab and the achieved rates of remission offer promise for enhancing...
The SAPHYR trial has provided...
10/16/2023
First Report Managed Care
Literature Review
A Look at the Impact, Prevalence of Demodex Blepharitis
12/06/2022
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the incidence, prevalence, and management of Demodex Blepharitis.
This article explores the...
12/06/2022
First Report Managed Care
Literature Review
Anti-CD38 Monoclonal Antibody for Multiple Myeloma: A Review of Clinical Trials
11/29/2022
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming clinical trials are testing the efficacy and safety of a monoclonal antibody in combination with other therapies for multiple myeloma.
Several ongoing and upcoming...
11/29/2022
First Report Managed Care
Literature Review
Isatuximab Demonstrates Significant PFS Among Patients With Multiple Myeloma
09/23/2022
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores the latest progression-free survival data for a multiple myeloma therapy option.
This literature review explores...
09/23/2022
First Report Managed Care
Literature Review
Bladder Cancers: What is Low-Grade Upper Tract Urothelial Carcinoma?
09/16/2022
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores key data related to the epidemiology, clinical presentation, and treatment considerations for patients with low-grade upper tract urothelial carcinoma.
This literature review explores...
09/16/2022
First Report Managed Care
Literature Review
Examining 177Lu-PSMA-617 as a Treatment for Metastatic Castration-resistant Prostate Cancer
09/16/2021
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we explore the data from the phase 3 VISION trial recently presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology and published in the New England Journal of Medicine, examining...
In this literature review, we...
09/16/2021
First Report Managed Care
Literature Review
Examining Benefits of Cannabidiol for Patients With Seizures
08/12/2021
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this literature review, we examine the latest data presented at the American Academy of Neurology’s (AAN) 2021 Virtual Annual Meeting regarding the use of CBD for patients with seizure disorders including TSC.  
For the purpose of this...
08/12/2021
First Report Managed Care
Literature Review
Examining Dry Eye Disease Flare Treatments
05/28/2021
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily applicable definition for dry eye disease, researchers believe the condition can be diagnosed with more consistency as well as inform future trials and research. 
With a newly proposed and easily...
05/28/2021
First Report Managed Care
Literature Review
Examining Lasmiditan for the Acute Treatment of Migraine Compared With Triptans
02/12/2021
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine foundation, oral and intranasal triptan therapy has proven consistently effective when used to treat migraine earlier in the attack; however, triptan therapy is not effective for all patients with migraine and cannot...
Per the American Migraine...
02/12/2021
First Report Managed Care

First Report

HCRU Burden of Chronic vs Episodic Migraine and Effect of Early vs Late Nonoral Triptan Use
Access to Acute Treatments for Migraine Can Reduce Costs for Employers, Health Care System
ICER Report Ranks Value, Clinical Effectiveness of Dupilumab and Other AD Treatments
Early Real-World Data Shows Increased Patient Satisfaction, Demonstrates Effectiveness for AD Therapy
“While this dataset is still maturing, in this as-observed interim analysis of a real-world study, dupilumab demonstrated early and sustained improvement in AD flares, symptoms, and disea...
First Report
HEOR First Report: A Deeper Look at the Benefits of Hemlibra
08/31/2020
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
High Persistence Examined With Dupilumab Among Adults With Atopic Dermatitis
Recent data showing high persistence rates for dupilumab therapy in patients with atopic dermatitis suggest that the treatment is well-tolerated and effective.
Decreased Medication, Utilization Costs Identified With Emicizumab-kxwh Therapy for Hemophilia
“In this analysis, emicizumab-kxwh therapy was associated with a decrease in the cost of HEM medications and cost and utilization of medical services,” explained researchers.
Cost-Saving Benefits Associated With Talazoparib Breast Cancer Treatment
When patients with gBRCA1/2mut HER2− advanced breast cancer switched from olaparib to talazoparib, a reduction in costs for US commercial health plans was observed.
Examining Economic Impact of Ixekizumab as Psoriatic Arthritis Treatment
Recent data shows that ixekizumab limits out-of-pocket spending for psoriatic arthritis treatment, despite associated higher pharmacy costs.
Reslizumab Associated With Symptomatic Improvements, Reduced Health Resource Utilization in Adults with Severe Eosinophilic Asthma
According to a study focused on real world data, adults with severe eosinophilic asthma experienced symptomatic improvements and decreased health care resource utilization when treated wi...
Weekly Dose of Hemophilia Factor VIII Therapy Delivers Significant Bleed Protection
Pegloticase Benefit Enhanced When Combined With Methotrexate for Patients With Chronic Gout
HCRU Burden of Chronic vs Episodic Migraine and Effect of Early vs Late Nonoral Triptan Use
Zanubrutinib Exhibits Superior Overall Response Rate for Adult Patients With Chronic Lymphocytic Leukemia
Access to Acute Treatments for Migraine Can Reduce Costs for Employers, Health Care System
Addition of Daratumumab to a Treatment Plan for Transplant Ineligible Patients With Multiple Myeloma Proves Beneficial
Atezolizumab Demonstrates Positive Disease-free Survival Benefit Among Patients With NSCLC
Data Supports Progression-Free Survival, Overall Survival for Long-Term CLL/SLL Treatment
ICER Report Ranks Value, Clinical Effectiveness of Dupilumab and Other AD Treatments
Dupilumab Reduces Type 2 Inflammation, May Offer Clinical Benefits for Multiple Comorbid Diseases

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use